<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01629823</url>
  </required_header>
  <id_info>
    <org_study_id>ALA-ACRC-13</org_study_id>
    <secondary_id>U01HL108730</secondary_id>
    <nct_id>NCT01629823</nct_id>
  </id_info>
  <brief_title>Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)</brief_title>
  <acronym>CPAP</acronym>
  <official_title>Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Lung Association Asthma Clinical Research Centers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>American Lung Association Asthma Clinical Research Centers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CPAP trial is a 3-arm parallel design randomized sham-controlled trial. Participants are
      randomly assigned in equal allocation to one of three treatments: CPAP 10 cm water (H₂O)
      (high) vs. CPAP 5 cm H₂O (medium) vs. CPAP Sham (less than 1 cm H₂O, Low). The treatment
      period is 12 weeks with airways reactivity assessed at baseline, 6 and 12 weeks of treatment
      and after a 2 week washout.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is now well established that failure to rhythmically apply strain to airway smooth muscle
      leads to change in the biomechanics of the smooth muscle characterized by shortened resting
      length and increased sensitivity to pharmacologic constrictors. Patients with asthma have
      physiologic airway characteristics that recapitulate this condition - increased airway tone
      and increased sensitivity to methacholine. It is our underlying hypothesis that asthma,
      although it may be initiated by allergic airway inflammation, is promoted by decreased tidal
      force fluctuations during recumbent sleep. If this is true, then treatments that increase
      tidal force fluctuations of airways should reverse these abnormalities. One treatment that
      increases tidal force fluctuations is continuous positive airway pressure (CPAP). CPAP
      prevents a fall in end expiratory lung volume and prevents closure of airways in dependent
      regions of the lung thereby permitting the stresses of tidal breathing to apply strain to
      airways. Preliminary data in 15 asthmatics showed that 1 week of 10cm H₂O nocturnal CPAP was
      associated with a remarkable 2.7-fold increase in the concentration of methacholine causing a
      20% fall in forced expiratory volume in 1 second (FEV₁) (PC20). The objective of this study
      is to conduct a randomized, sham-controlled, multicenter study of 5 and 10 cm H₂O CPAP in
      order to verify these findings; to assess the effect of nocturnal CPAP on airways reactivity;
      to determine the durability of the effect over 12 weeks; to assess the safety, tolerability
      and adherence to this treatment; and to explore if there are clinically meaningful benefits.
      The study will be conducted at 18 centers of the American Lung Association-Asthma Clinical
      Research Centers (ALA-ACRC) with the Data Coordinating Center (DCC) at Johns Hopkins
      University.

      A substudy of High Resolution Computed Tomography (HRCT) will also be conducted at a subset
      of the ACRC clinics. A total of 54 subjects (18 per arm)who are randomized in the main study
      will be voluntarily enrolled in the substudy to compare the structural changes in the airways
      across treatment groups and to correlate structural changes with the physiological changes. A
      total of two visits will be conducted. HRCT Visit 1 will be performed after randomization in
      the main CPAP study, and prior to initiation of CPAP. HRCT Visit 2 will be performed between
      weeks 10 and 12 of CPAP, at a different day or prior of methacholine challenge testing.Two CT
      scans will be performed each at different lung volume at each visit (Total of 4 scans for the
      study duration). The first volume will be at Total Lung Capacity (TLC), followed by another
      CT scan at Functional Residual Capacity (FRC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methacholine Reactivity</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>The primary outcome measure was the change in provocative concentration of methacholine causing a 20% fall in forced expiratory volume in 1 second (FEV₁) (PC20) from baseline to 12 weeks. Modified American Thoracic Society guidelines were followed for pre-bronchodilator spirometry and methacholine challenge testing using the 5 breath dosimeter technique. Up to eleven doses, each a doubling concentration of methacholine (Provocholine™), were inhaled starting at 0.03 mg/mL until a 20% or greater fall in FEV₁ occurred; the maximum dose was 32 mg/mL. Breaths each of doubling concentrations of methacholine were inhaled from a calibrated DeVilbiss™ 646 nebulizer.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">209</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CPAP less than 1 cm H₂O</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPAP 10cm H₂O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPAP 5cm H₂O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)</intervention_name>
    <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.</description>
    <arm_group_label>CPAP less than 1 cm H₂O</arm_group_label>
    <arm_group_label>CPAP 10cm H₂O</arm_group_label>
    <arm_group_label>CPAP 5cm H₂O</arm_group_label>
    <other_name>ResMed CPAP S9 series: Elite &amp; Escape</other_name>
    <other_name>Masks: Swift FX, Mirage FX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  15 - 60 years of age at V1

          -  Physician diagnosis of asthma and on prescribed asthma medication for at least the
             past 12 months at V1

          -  Pre-bronchodilator FEV₁ greater than or equal to 75% predicted at V1 (to minimize the
             likelihood that variability in FEV₁ will preclude participants from having
             methacholine challenges in follow-up visits)

          -  Airways reactivity: Methacholine bronchial challenge with concentration of
             methacholine causing a 20% fall in forced expiratory volume in 1 second (PC ₂₀) less
             than or equal to 8 mg/mL at V1

          -  Stable asthma defined by no change in treatment, emergency department (ED) visit,
             hospitalization, or urgent health care visit for asthma for the 8 weeks prior to
             screening

          -  Non-smoker for more than 6 months and less than or equal to 10 pack-year history of
             smoking

          -  Ability and willingness to provide informed consent

          -  If receiving immunotherapy, must have had stable therapy for the 8 weeks prior to
             screening

          -  Spend a minimum of six hours per night in bed on average

          -  Willingness to sleep 5 days a week on average in the same place for the next 4 months

          -  For women of child bearing potential; not pregnant, not lactating and agree to
             practice and adequate birth control method (abstinence, combination barrier and
             spermicide, or hormonal) for the duration of the study

        Exclusion criteria

          -  Weight less than or equal to 66 lbs. (30kg) at V1

          -  BMI greater than or equal to 35 at V1

          -  Acute respiratory illness in the month prior to screening

          -  Systemic corticosteroid therapy during the 3 months preceding screening

          -  History of sleep apnea by self-report High risk of sleep apnea as assessed by
             Multivariable Apnea Prediction (MAP) Index; high risk defined as probability that is
             equal to or greater than 20%

          -  Chronic diseases (other than asthma) that in the opinion of the investigator would
             interfere with participation in the trial or put the participant at risk by
             participation, e.g. non-skin cancer, chronic diseases of the lung (other than asthma),
             chronic heart diseases, endocrine diseases, liver, kidney or nervous system diseases,
             or immunodeficiency, any pre-existing conditions that may be contraindications to
             positive airway pressure including: severe bullous lung disease, pneumothorax,
             pathologically low blood pressure, dehydration, cerebrospinal fluid leak, recent
             cranial surgery, trauma, bypassed upper (supraglottic) airway

          -  Known sleep disorders that are currently under treatment by a sleep specialist

          -  Known intolerance to methacholine

          -  Absolute contraindications to methacholine that include: current use of
             beta-adrenergic blocking agent, heart attack or stroke in the last 3 months,
             uncontrolled hypertension, known aortic aneurysm

          -  Use of investigative drugs or intervention trials in the 30 days prior to screening or
             during the duration of the study

          -  Prior use of CPAP for any reason Homelessness, lack of telephone access, or intention
             to move within the next 4 months of the trial.

          -  For blinding purposes, members from the same household cannot participate in the study
             at the same time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Holbrook, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami/ University of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Consortium</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital and Health Care Center, Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center, The Ernest N. Morial Asthma, Allergy and Respiratory Disease Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri, Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/ St. Louis University</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hofstra University School of Medicine</name>
      <address>
        <city>Hempstead</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University - New York University Consortium</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center/ Columbus Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New England Consortium</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <results_first_submitted>January 30, 2017</results_first_submitted>
  <results_first_submitted_qc>April 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2017</results_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American Lung Association Asthma Clinical Research Centers</investigator_affiliation>
    <investigator_full_name>Robert A. Wise, M.D.</investigator_full_name>
    <investigator_title>Robert A. Wise, M.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>209 individuals were enrolled in the study. 15 of those participants were excluded from data analysis due to significant data irregularities at one clinical site</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CPAP Less Than 1 cm Water (H₂O)</title>
          <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>CPAP 5cm H₂O</title>
          <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>CPAP 10cm H₂O</title>
          <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Trial Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pre-diluent FEV₁ predicted &lt;70%</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Out-of-window visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to hold medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Safety</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CPAP Less Than 1 cm H₂O</title>
          <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.</description>
        </group>
        <group group_id="B2">
          <title>CPAP 5cm H₂O</title>
          <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.</description>
        </group>
        <group group_id="B3">
          <title>CPAP 10cm H₂O</title>
          <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="59"/>
            <count group_id="B4" value="194"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="23" upper_limit="47"/>
                    <measurement group_id="B2" value="31" lower_limit="20" upper_limit="40"/>
                    <measurement group_id="B3" value="25" lower_limit="18" upper_limit="39"/>
                    <measurement group_id="B4" value="31" lower_limit="20" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Symptom Utility Index (ASUI) Score</title>
          <description>The Asthma Symptom Utility Index (ASUI) is a brief, interviewer-administered, patient preference-based scale assessing frequency and severity of selected asthma-related symptoms and treatment side effects. The minimum score is 0 and the maximum score is 1, with lower scores indicating more symptoms.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.89" lower_limit="0.83" upper_limit="0.94"/>
                    <measurement group_id="B2" value="0.94" lower_limit="0.85" upper_limit="1.00"/>
                    <measurement group_id="B3" value="0.92" lower_limit="0.86" upper_limit="0.98"/>
                    <measurement group_id="B4" value="0.92" lower_limit="0.84" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Control Test (ACT) Score</title>
          <description>The Asthma Control Test (ACT) is a validated self-administered survey utilizing 5 questions to assess asthma control on a scale from 1 (poor control) to 5 (total control) in individuals 12 years and older. By answering all 5 questions a patient with asthma can obtain a score that may range between 5 and 25. Asthma control is considered a good characteristic for a person with asthma and therefore a higher score is considered a better outcome.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21" lower_limit="19" upper_limit="23"/>
                    <measurement group_id="B2" value="22" lower_limit="20" upper_limit="24"/>
                    <measurement group_id="B3" value="22" lower_limit="20" upper_limit="23"/>
                    <measurement group_id="B4" value="22" lower_limit="20" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marks Asthma Quality of Life</title>
          <description>Marks Asthma Quality of Life Questionnaire (AQLQ) measures physical and emotional asthma specific quality of life during the past four weeks. The minimum score is 0 and the maximum score is 80, with lower scores indicating better quality of life. The scale is for use in adults only (individuals aged 18 or older).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" lower_limit="5" upper_limit="21"/>
                    <measurement group_id="B2" value="7" lower_limit="3" upper_limit="11"/>
                    <measurement group_id="B3" value="6" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="B4" value="7" lower_limit="4" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinonasal Questionnaire (SNQ-6)</title>
          <description>The Sinonasal Questionnaire (SNQ-6) is a six-item questionnaire designed to diagnose chronic sinonasal disease in patients with asthma. This questionnaire asks about runny nose, postnasal drip, need to blow the nose, facial pain or pressure, and nasal obstruction. Possible answers include never (zero points), 1–4 times per month (1 point), 2–6 times per week (2 points), and daily (3 points). The number of points is then averaged. The minimum score is 0 and the maximum score is 3, with higher scores indicating higher frequency of sinonasal disease symptoms.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" lower_limit="0.6" upper_limit="1.6"/>
                    <measurement group_id="B2" value="0.8" lower_limit="0.4" upper_limit="1.4"/>
                    <measurement group_id="B3" value="0.8" lower_limit="0.4" upper_limit="1.2"/>
                    <measurement group_id="B4" value="0.8" lower_limit="0.4" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PC20</title>
          <description>The PC20 is the concentration of methacholine needed to produce a 20% fall in forced expiratory volume in 1 second (FEV₁) from baseline.</description>
          <units>mg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.06" lower_limit="0.47" upper_limit="2.95"/>
                    <measurement group_id="B2" value="0.96" lower_limit="0.30" upper_limit="2.66"/>
                    <measurement group_id="B3" value="0.89" lower_limit="0.28" upper_limit="2.33"/>
                    <measurement group_id="B4" value="0.98" lower_limit="0.33" upper_limit="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV₁</title>
          <description>FEV₁ stands for forced expiratory volume in one second, the volume that has been exhaled at the end of the first second of forced expiration.</description>
          <units>L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" lower_limit="2.4" upper_limit="3.5"/>
                    <measurement group_id="B2" value="3.1" lower_limit="2.6" upper_limit="3.7"/>
                    <measurement group_id="B3" value="3.0" lower_limit="2.7" upper_limit="3.4"/>
                    <measurement group_id="B4" value="3.1" lower_limit="2.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent-predicted FEV₁</title>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.0" lower_limit="84.0" upper_limit="96.3"/>
                    <measurement group_id="B2" value="90.9" lower_limit="81.9" upper_limit="99.9"/>
                    <measurement group_id="B3" value="91.8" lower_limit="80.7" upper_limit="98.0"/>
                    <measurement group_id="B4" value="90.6" lower_limit="82.7" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced vital capacity (FVC)</title>
          <description>Forced vital capacity: the determination of the vital capacity from a maximally forced expiratory effort.</description>
          <units>L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" lower_limit="3.3" upper_limit="4.5"/>
                    <measurement group_id="B2" value="4.2" lower_limit="3.5" upper_limit="4.9"/>
                    <measurement group_id="B3" value="3.9" lower_limit="3.4" upper_limit="4.5"/>
                    <measurement group_id="B4" value="4.1" lower_limit="3.4" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily use of inhaled corticosteroid (ICS)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily use of combined inhaled corticosteroid/long acting beta agonist (ICS/LABA)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily use of anti-leukotriene</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.8" lower_limit="23.0" upper_limit="29.8"/>
                    <measurement group_id="B2" value="26.2" lower_limit="22.3" upper_limit="28.9"/>
                    <measurement group_id="B3" value="24.1" lower_limit="22.0" upper_limit="28.8"/>
                    <measurement group_id="B4" value="25.7" lower_limit="22.3" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Former smoker</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Methacholine Reactivity</title>
        <description>The primary outcome measure was the change in provocative concentration of methacholine causing a 20% fall in forced expiratory volume in 1 second (FEV₁) (PC20) from baseline to 12 weeks. Modified American Thoracic Society guidelines were followed for pre-bronchodilator spirometry and methacholine challenge testing using the 5 breath dosimeter technique. Up to eleven doses, each a doubling concentration of methacholine (Provocholine™), were inhaled starting at 0.03 mg/mL until a 20% or greater fall in FEV₁ occurred; the maximum dose was 32 mg/mL. Breaths each of doubling concentrations of methacholine were inhaled from a calibrated DeVilbiss™ 646 nebulizer.</description>
        <time_frame>12 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPAP Less Than 1 cm H2O</title>
            <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.</description>
          </group>
          <group group_id="O2">
            <title>CPAP 5cm H2O</title>
            <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.</description>
          </group>
          <group group_id="O3">
            <title>CPAP 10cm H2O</title>
            <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Methacholine Reactivity</title>
          <description>The primary outcome measure was the change in provocative concentration of methacholine causing a 20% fall in forced expiratory volume in 1 second (FEV₁) (PC20) from baseline to 12 weeks. Modified American Thoracic Society guidelines were followed for pre-bronchodilator spirometry and methacholine challenge testing using the 5 breath dosimeter technique. Up to eleven doses, each a doubling concentration of methacholine (Provocholine™), were inhaled starting at 0.03 mg/mL until a 20% or greater fall in FEV₁ occurred; the maximum dose was 32 mg/mL. Breaths each of doubling concentrations of methacholine were inhaled from a calibrated DeVilbiss™ 646 nebulizer.</description>
          <units>mg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PC20, 12-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" lower_limit="1.30" upper_limit="3.49"/>
                    <measurement group_id="O2" value="1.48" lower_limit="0.96" upper_limit="2.28"/>
                    <measurement group_id="O3" value="1.44" lower_limit="0.91" upper_limit="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC20, post-washout (14 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="0.96" upper_limit="2.69"/>
                    <measurement group_id="O2" value="1.37" lower_limit="0.91" upper_limit="2.07"/>
                    <measurement group_id="O3" value="1.27" lower_limit="0.81" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Both the 5 and 10cm groups were compared to the control group, &lt;1cm H₂O</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <p_value_desc>Comparison of 5cm group to control. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Regression, Linear</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CPAP Less Than 1 cm H₂O</title>
          <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.</description>
        </group>
        <group group_id="E2">
          <title>CPAP 5cm H₂O</title>
          <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.</description>
        </group>
        <group group_id="E3">
          <title>CPAP 10cm H₂O</title>
          <description>Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anemia</sub_title>
                <description>Hospitalization due to chronic blood loss and fatigue</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pyleonephritis</sub_title>
                <description>Kidney infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear or sinus discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Drying of nose, mouth, and/or throat</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="59"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nose irritation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Congestion, runny nose, sneezing</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="52"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="52"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Increased work breathing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Janet T Holbrook, PhD, MPH</name_or_title>
      <organization>ALA-ACRC</organization>
      <phone>443-287-3170</phone>
      <email>jholbro1@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

